Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BWC4221
- Development stage
- Preclinical
- Lead developer
- Bugworks Research
- Modality
- Small Molecules
01
Overview
BWC4221 (also known as BWC3416) is a preclinical-stage small molecule inhibitor of methionine adenosyltransferase 2A (MAT2A) being developed by Bugworks Research. It is designed as a synthetic-lethal therapeutic strategy targeting methylthioadenosine phosphorylase (MTAP)-deleted cancers, which exhibit a dependency on MAT2A. MTAP deletion is a common genomic alteration in various malignancies, including pancreatic, lung, bladder, gastrointestinal cancers, glioblastoma, and mesothelioma. By inhibiting MAT2A, BWC4221 aims to selectively disrupt cancer cell survival while sparing normal tissues. The drug is currently in the lead generation phase of preclinical development.
02
Targets
MAT2A (Methionine adenosyltransferase 2A)
Beyond the preview
Go deeper on BWC4221.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BWC4221.